Clinical Trials Browser

Neoplasms × apatinib × Clear all

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Phase 1 Completed

Neoplasm Metastasis, Neoplasms

NCT01192971 2023-03-03

HCC

Phase 2 Completed

Neoplasms

NCT03042611 2022-07-08

ANGEL

Phase 3 Completed

460 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT03475589 2020-05-12

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Phase 4 Unknown

Neoplasms, Ovarian Neoplasms

NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT03889626 2019-03-26

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Phase 3 Unknown

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Diseases, Stomach Neoplasms

NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Phase 4 Completed

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Phase 2 Unknown

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT01497704 2017-10-02

Dose-Escalation and Safety Trial of YN968D1

Phase 1/2 Completed

Neoplasms

NCT03199677 2017-07-02

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Phase 2 Unknown

Neoplasms, Thyroid Neoplasms

NCT02836171 2017-02-27

Effect of Itraconazole on the Pharmacokinetics of Apatinib

Phase 1 Completed

Neoplasms

NCT02836821 2017-02-27

Effect of Rifampicin on the Pharmacokinetics of Apatinib

Phase 1 Completed

Neoplasms

NCT01270386 2012-02-10

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00633490 2008-07-22

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Phase 1 Unknown

Neoplasms